Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Long-Term Debt Issuances: 2020-2021

Historic Long-Term Debt Issuances for Janux Therapeutics (JANX) over the last 2 years, with Dec 2021 value amounting to $124.8 million.

  • Janux Therapeutics' Long-Term Debt Issuances was N/A to $68.8 million in Q2 2021 from the same period last year, while for Jun 2021 it was $129.3 million, marking a year-over-year change of. This contributed to the annual value of $124.8 million for FY2021, which is 1294.07% up from last year.
  • Latest data reveals that Janux Therapeutics reported Long-Term Debt Issuances of $124.8 million as of FY2021, which was up 1,294.07% from $9.0 million recorded in FY2020.
  • Janux Therapeutics' Long-Term Debt Issuances' 5-year high stood at $124.8 million during FY2021, with a 5-year trough of $9.0 million in FY2020.
  • Moreover, its 2-year median value for Long-Term Debt Issuances was $66.9 million (2020), whereas its average is $66.9 million.
  • Data for Janux Therapeutics' Long-Term Debt Issuances shows a peak YoY spiked of 1,294.07% (in 2021) over the last 5 years.
  • Over the past 2 years, Janux Therapeutics' Long-Term Debt Issuances (Yearly) stood at $9.0 million in 2020, then soared by 1,294.07% to $124.8 million in 2021.